general medicine

普通医学
  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    自1967年以来,马尔堡病毒(MARV)经常影响人们,导致多次爆发。目前尚无针对致命马尔堡病毒病(MVD)的授权疗法,这对全球公共卫生构成了迫在眉睫的风险。到目前为止,MVD已经夺走了许多人的生命,随着整个非洲大陆的病例数量增加。因此,进行了审查,以分析MVD的地理分布,死亡率,传播途径,以及诊断和治疗方式。
    PubMed,Scopus,WebofScience,谷歌学者,和ProMED服务器用于按照PRISMA指南进行系统搜索。对结果进行列表和分析。
    共有11项研究(7例病例报告和4例病例系列)纳入最终分析,并对21例MVD进行分析。最常见的症状是发烧(66.67%),呕吐(57.14%),头痛(52.38%),腹泻(52.38%),疼痛(47.62%)。最常用的诊断试验是RT-PCR(42.11%)。接触传播(50%)和人畜共患传播(37.5%)是最普遍的传播途径。抗生素(61.5%)是一线治疗。最常见的并发症是出血(60%)和凝血功能障碍(33.3%)。死亡率为57.1%。
    为了避免灾难性的后果,重申MVD早期诊断和治疗的必要性至关重要。
    UNASSIGNED: Marburg virus (MARV) has regularly affected people since 1967 causing multiple outbreaks. There are presently no authorized therapies for the fatal Marburg virus disease (MVD), which poses an imminent risk to global public health. The MVD has so far claimed the lives of numerous people, with an increased number of cases being seen throughout the African continent. Hence, a review was carried out to analyze the geographical distribution of MVD, mortality, routes of transmission, and diagnostic and treatment modalities.
    UNASSIGNED: PubMed, Scopus, Web of Science, Google Scholar, and ProMED servers were used to conduct a systematic search in compliance with the PRISMA guidelines. The results were tabulated and analyzed.
    UNASSIGNED: A total of 11 studies (7 case reports and 4 case series) were included in the final analysis, and 21 cases of MVD were analyzed. The most frequent symptoms were fever (66.67%), vomiting (57.14%), headache (52.38%), diarrhea (52.38%), and pain (47.62%). The most commonly used diagnostic test was RT-PCR (42.11%). Contact transmission (50%) and zoonotic transmission (37.5%) were the most prevalent routes of transmission. Antibiotics (61.5%) were the first line of treatment. The most common complications were hemorrhage (60%) and coagulopathies (33.3%). The mortality rate was 57.1%.
    UNASSIGNED: To avoid disastrous consequences, it is essential to reiterate the necessity of early diagnosis and treatment of MVD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    研究人员最近利用ChatGPT作为撰写临床信件的工具,强调其产生准确和善解人意的沟通能力。在这里,我们展示了ChatGPT在讲普通话的门诊诊所中作为医疗助理的潜在应用,旨在提高高患者容量设置中的患者满意度。ChatGPT在中医执业考试的临床知识部分平均得分为72.4%,排名前20百分位。它还证明了其在非英语环境中进行临床交流的潜力。我们的研究表明,ChatGPT可以在讲中文的门诊环境中充当医生和患者之间的接口,可能延伸到其他语言。然而,需要进一步优化,包括医疗特定数据集的培训,严格的测试,隐私合规性,与现有系统集成,用户友好的界面,以及制定医疗专业人员指南。在广泛实施之前,对照临床试验和监管部门的批准是必要的。随着聊天机器人融入医疗实践变得更加可行,严格的早期调查和试点研究可以帮助减轻潜在风险。
    Researchers recently utilized ChatGPT as a tool for composing clinic letters, highlighting its ability to generate accurate and empathetic communications. Here we demonstrated the potential application of ChatGPT as a medical assistant in Mandarin Chinese-speaking outpatient clinics, aiming to improve patient satisfaction in high-patient volume settings. ChatGPT achieved an average score of 72.4% in the Chinese Medical Licensing Examination\'s Clinical Knowledge section, ranking within the top 20th percentile. It also demonstrated its potential for clinical communication in non-English speaking environments. Our study suggests that ChatGPT could serve as an interface between physicians and patients in Chinese-speaking outpatient settings, possibly extending to other languages. However, further optimization is required, including training on medical-specific datasets, rigorous testing, privacy compliance, integration with existing systems, user-friendly interfaces, and the development of guidelines for medical professionals. Controlled clinical trials and regulatory approval are necessary before widespread implementation. As chatbots\' integration into medical practice becomes more feasible, rigorous early investigations and pilot studies can help mitigate potential risks.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:高血压是COVID-19肺炎中最常见的合并症之一。然而,它是否是COVID-19严重程度和死亡率的独立因素尚未研究。
    方法:在本研究中,从2020年1月12日至2020年3月25日,纳入了736例经PCR确认诊断为COVID-19的患者。所有患者根据是否高血压分为两组。在倾向评分匹配(PSM)以消除基线数据中不匹配的干扰之后,分析血管紧张素II受体阻滞剂(ARB)/ACE抑制剂应用的临床特征和结局.
    结果:共有220例(29.9%)高血压患者,516例(70.1%)患者无高血压。PSM消除了两组之间的人口统计学和合并症差异。在所有参与者中,32例患者死亡(4.3%死亡率),包括高血压组220人中的17人(7.7%)和非高血压组516人中的15人(2.9%).高血压组重症监护病房(ICU)住院发生率(12.8%)高于非高血压组(5.3%)(p<0.05)。Logistic回归分析显示高血压是死亡的独立危险因素,不是其他合并症。Kaplan-Meier分析显示,PSM前后高血压组死亡率高于非高血压组(p<0.05)。ICU治疗差异无统计学意义,有或没有ARBs/ACE抑制剂的高血压患者的死亡率和住院时间(p>0.05)。
    结论:高血压是COVID-19患者病情严重程度和死亡率的独立危险因素。患有COVID-19的高血压患者不应停用ARBs/ACE抑制剂。
    OBJECTIVE: Hypertension is one of the most common comorbidities in COVID-19 pneumonia. However, whether it is an independent factor on the severity and mortality of COVID-19 has not been studied.
    METHODS: In this study, 736 patients with a PCR-confirmed diagnosis of COVID-19 were included from 12 January 2020 to 25 March 2020. All patients were divided into two groups according to whether or not they were hypertensive. After propensity score matching (PSM) to remove the interference of mismatches in the baseline data, the clinical characteristics and outcomes of angiotensin II receptor blocker (ARB)/ACE inhibitors application were analysed.
    RESULTS: A total of 220 (29.9%) patients were hypertensive, and 516 (70.1%) patients were not hypertensive. PSM eliminated demographic and comorbidity differences between the two groups. Of all participants, 32 patients died (4.3% mortality), including 17 out of 220 in the hypertension group (7.7%) and 15 out of 516 in the non-hypertension group (2.9%). The incidence of intensive care unit (ICU) stay in the hypertension group (12.8%) was higher than in the non-hypertension group (5.3%) (p<0.05). Logistic regression analysis showed that hypertension was an independent risk factor for death, not other comorbidities. Kaplan-Meier analysis showed that mortality was higher in the hypertension group than in the non-hypertension group before and after PSM (p<0.05). There was no statistically significant difference in ICU therapy, mortality and hospitalisation time between hypertensive patients with or without ARBs/ACE inhibitors (p>0.05).
    CONCLUSIONS: Hypertension was an independent risk factor for the severity and mortality of patients with COVID-19. ARBs/ACE inhibitors should not be discontinued in hypertensive patients with COVID-19.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    OBJECTIVE: Hypertension is one of the most common comorbidities in COVID-19 pneumonia. However, whether it is an independent factor on the severity and mortality of COVID-19 has not been studied.
    METHODS: In this study, 736 patients with a PCR-confirmed diagnosis of COVID-19 were included from 12 January 2020 to 25 March 2020. All patients were divided into two groups according to whether or not they were hypertensive. After propensity score matching (PSM) to remove the interference of mismatches in the baseline data, the clinical characteristics and outcomes of angiotensin II receptor blocker (ARB)/ACE inhibitors application were analysed.
    RESULTS: A total of 220 (29.9%) patients were hypertensive, and 516 (70.1%) patients were not hypertensive. PSM eliminated demographic and comorbidity differences between the two groups. Of all participants, 32 patients died (4.3% mortality), including 17 out of 220 in the hypertension group (7.7%) and 15 out of 516 in the non-hypertension group (2.9%). The incidence of intensive care unit (ICU) stay in the hypertension group (12.8%) was higher than in the non-hypertension group (5.3%) (p<0.05). Logistic regression analysis showed that hypertension was an independent risk factor for death, not other comorbidities. Kaplan-Meier analysis showed that mortality was higher in the hypertension group than in the non-hypertension group before and after PSM (p<0.05). There was no statistically significant difference in ICU therapy, mortality and hospitalisation time between hypertensive patients with or without ARBs/ACE inhibitors (p>0.05).
    CONCLUSIONS: Hypertension was an independent risk factor for the severity and mortality of patients with COVID-19. ARBs/ACE inhibitors should not be discontinued in hypertensive patients with COVID-19.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Historical Article
    The first official general medicine was established in the United States, and society of general medicine established in 1947. After that the European and American countries began to study of general medicine and construct system. In 1966, the commonwealth launched the first global residency training program in general medicine.At present, many countries have formed a perfect general practitioner training system. In 1988, the concept of general medicine was introduced into China. In 1989, the Chinese Medical Association established the General Medicine Education Committee, marked the beginning of general medical education in China. In 1993, General Medicine Branch of Chinese Medical Association was set up, was a symbol of the birth of general medicine in China. Compared with some European and American countries, China\'s general medicine was a late starter, and the training of general practitioners has experienced the development of diversification, at present, it is in line with the international training mode.
    全科医学最早官方确立是在美国,1947年成立全科医学学会,之后欧美国家均开始了对全科医学的研究及体系建设,1966年英联邦启动了全球第一个全科医学住院医师培训项目,目前已形成了完善的全科医师培养体系。1988年全科医学概念引入中国;1989年,中华医学会成立了\"全科医学教育委员会\",标志着中国全科医学教育的正式开始;1993年,\"中华医学会全科医学分会\"成立,标志着全科医学学科在中国的诞生。相较于西方欧美国家,中国全科医学起步晚,对全科医师的培养经历了多元化的发展,目前正在与国际培养模式相接轨。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号